Fuji Pharma Co. Ltd.
https://www.fujipharma.jp/english/ir/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Fuji Pharma Co. Ltd.
Finance Watch: Public Companies Pursue All Options To Fund R&D, Launches
Public Company Edition: Follow-on offerings may not be the favored path to funding development programs or product launches after major milestones in the current environment. Amicus secured $430m in a deal with Blackstone, while OPKO’s Modex garnered up to $168m from BARDA.
Asia Deal Watch: US Biotech LIB Partners In Greater China With Hasten On PCSK9 Therapy
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
Asia Deal Watch: Astellas Begins 2023 Signing Rare Disease Tie-Ups With Selecta, Twist
Evopoint and Kaken also ring in the new year with multiple deals. Biocytogen licenses antibodies against a specified target derived from its RenMice platform technology to Hansoh Pharma.
Alvotech Achieves Japan Milestone, Expands In Canada
Alvotech has swiftly advanced in Japan and Canada, as part of its mission to introduce its pipeline of biosimilars across the globe.
Company Information
- Industry
- Distributors
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- Radiopharmaceuticals, Contrast Agents
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
-
Diagnostic Imaging Equipment & Supplies
-
In Vitro Diagnostics
- Chemistry, Immunoassay
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice